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Obesity is associated with increased mortality and accelerated decline in kidney function in
the general population. Little is known about the effect of obesity in younger and older pre-
dialysis patients. The aim of this study was to assess the extent to which obesity is a risk fac-
tor for death or progression to dialysis in younger and older patients on specialized pre-dialy-
sis care.
Method
In a multicenter Dutch cohort study, 492 incident pre-dialysis patients (>18y) were included
between 2004–2011 and followed until start of dialysis, death or October 2016. We grouped
patients into four categories of baseline body mass index (BMI): <20, 20–24 (reference),
25–29, and30 (obesity) kg/m2 and stratified patients into two age categories (<65y or
65y).
Results
The study population comprised 212 patients younger than 65 years and 280 patients 65
years and older; crude cumulative risk of dialysis and mortality at the end of follow-up were
66% and 4% for patients <65y and 64% and 14%, respectively, for patients65y. Among
the <65y patients, the age-sex standardized combined outcome rate was 2.3 times higher in
obese than those with normal BMI, corresponding to an excess rate of 35 events/100
patient-years. After multivariable adjustment the hazard ratios (HR) (95% CI) for the com-
bined endpoint by category of increasing BMI were, for patients <65y, 0.92 (0.41–2.09), 1
(reference), 1.76 (1.16–2.68), and 1.81 (1.17–2.81). For patients65y the BMI-specific
HRs were 1.73 (0.97–3.08), 1 (reference), 1.25 (0.91–1.71) and 1.30 (0.79–1.90). In the
competing risk analysis, taking dialysis as the event of interest and death as a competing
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event, the BMI-specific multivariable adjusted subdistribution HRs (95% CI) were, for
patients <65y, 0.90 (0.38–2.12), 1 (reference), 1.47 (0.96–2.24) and 1.72 (1.15–2.59). For
patients65y the BMI-specific SHRs (95% CI) were 1.68 (0.93–3.02), 1 (reference), 1.50
(1.05–2.14) and 1.80 (1.23–2.65).
Conclusion
We found that obesity in younger pre-dialysis patients and being underweight in older pre-
dialysis patients are risk factors for starting dialysis and for death, compared with those with
a normal BMI.
Introduction
The global prevalence of end-stage renal disease (ESRD) that requires renal replacement ther-
apy (RRT) has risen steadily and has more than doubled since 1990 [1,2]. Most notably, the
proportion of ESRD patients aged 65 years or older has grown considerably, comprising more
than 66% of all maintenance dialysis patients in industrialized countries. The number of ESRD
patients aged 65–74 years and>75 years grew from 2005 to 2010 by 11% and 4%, respectively
[3]. Identifying potentially modifiable risk factors for ESRD and death is important for tar-
geted prevention.
The prevalence of obesity among adults aged 20 to 74 years has increased in the past 20
years from 15 to 35% in the United States, and from 10% to>30% in the Netherlands [4,5].
Obesity is associated with accelerated decline of kidney function as well as mortality in the
general population, as well as among kidney transplant and dialysis patients [6–10]. An analy-
sis of the REIN trial (mean estimated glomerular filtration rate [eGFR] 40 ml/min/1.73m2)
also showed an increased incidence of ESRD in obese compared with non-obese patients [11].
Obesity is a major risk factor for the development of type 2 diabetes and hypertension, which
are the primary causes of ESRD in US, Asia as well as in the Netherlands [1,9,12]. Other mech-
anisms by which obesity exerts its detrimental effects on kidney function decline are mediated
via glomerular hyperfiltration, activation of the renin-angiotensin system, and the change of
adipose tissue into a pro-inflammatory state that may cause focal and segmental glomerulo-
sclerosis [13,14].
Obesity is a less important risk factor for death in the elderly compared with younger indi-
viduals in the general population [10]. We previously showed that in contrast to older incident
dialysis patients, younger patients with obesity had a substantially elevated risk for death [9].
The aim of this study was to assess the extent to which obesity is a risk factor for start of
dialysis, kidney function decline and mortality in patients on specialized pre-dialysis care.
Since obesity is a potentially modifiable risk factor, it is important to identify patients who are
susceptible to the detrimental effects of adiposity for targeted prevention of ESRD or prema-
ture death. Differences in the effect of obesity on ESRD and mortality between younger and
older pre-dialysis patients have not been studied. Here we investigate the extent to which the
effect of obesity on ESRD or death differs between younger (<65y) and older (65y) pre-dial-
ysis patients. These results might inform care guidelines for pre-dialysis patients.
Obesity, death or dialysis in pre-dialysis patients
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Methods
Study design and population
The PRE-dialysis PAtient REcord-2 (PREPARE-2) study is a prospective cohort study of inci-
dent pre-dialysis patients (18y) recruited in one of 25 nephrology specialized pre-dialysis
outpatient clinics in the Netherlands, as previously described (S1 Appendix) [15]. Briefly, 502
pre-dialysis patients (eGFR<30 ml/min/1.73m2) with progressive loss of kidney function
were included between July 2004 and June 2011, at the time of referral to a specialized pre-dial-
ysis outpatient clinic. Patients with a failing kidney transplant who were transplanted at least
one year ago were also eligible for inclusion. All patients were treated by their nephrologist in
accordance with the treatment guidelines of the Dutch Federation of Nephrology, guidelines
partly based on the K/DOQI and EBPG guidelines [16–18]. Patients were followed from the
start of pre-dialysis care until start of dialysis, kidney transplantation, death or censoring. Cen-
soring occurred in the event of refusal for further participation, recovery of kidney function,
moving to an outpatient clinic not participating in the PREPARE-2 study, loss to follow-up or
on October, 2016 (end of follow-up), whichever came first. This study was approved by the
medical ethics committee or the institutional review boards (as appropriate) of all participating
centers (S2 Appendix). All participants gave their written informed consent before study
inclusion.
Body mass index
To measure adiposity at baseline, we used body mass index (BMI), calculated as weight in kilo-
grams divided by the square of height in meters. Following the World Health Organization
(WHO) guidelines, obesity was defined as a BMI of 30 kg/m2 or greater, and overweight as a
BMI of 25–29 kg/m2. We defined normal weight as a BMI of 20–24 kg/m2, which is within the
normal range of 18–24 kg/m2 according to the WHO, and we considered this group a priori as
the reference category [19]. We defined underweight as a BMI less than 20 kg/m2.
Other demographic and clinical data
Data on demography, primary kidney disease, diabetes, history of cardiovascular disease
(myocardial infarction and cerebrovascular accident), and medication prescriptions were col-
lected at the start of specialized pre-dialysis care and at subsequent 6-month intervals. Patients
were classified as either current smokers of cigarettes, former or never smokers. Laboratory
data were extracted from the electronic hospital information systems or medical records. Pri-
mary kidney disease was classified according to the codes of the European Renal Association-
European Dialysis and Transplantation Association [20]. We grouped patients into four classes
of primary kidney disease: glomerulonephritis, diabetes mellitus, renal vascular disease, and
other kidney diseases. We estimated GFR with the creatinine-based Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation from 2009 [21].
Data analysis
Death and start of dialysis are competing risks. In older compared with younger pre-dialysis
patients there is an increasing risk of death that precedes the onset of ESRD. Among younger
pre-dialysis patients there were few deaths. Therefore, our study endpoint was a composite
variable, ESRD that requires dialysis, or death. We censored follow-up at pre-emptive kidney
transplantation. Since the effects of obesity may occur after a long induction period, we classi-
fied patients by their BMI at baseline [22]. We divided patients into two age categories, using
65y as the boundary point [9]. To compare the association of BMI and the combined endpoint
Obesity, death or dialysis in pre-dialysis patients
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between younger (<65y) and older (65y) pre-dialysis patients, patients were divided into
eight categories based on their age (<65y or65y) and baseline BMI:<20, 20–24, 25–29 and
30 kg/m2.
We assessed the relation between BMI categories and the composite endpoint using several
methods. First, absolute incidence rates were calculated within each age and BMI category.
Second, age-sex standardized dialysis-mortality rates were calculated for each BMI category,
using 14 5-year age groups for each sex. Within each of the two broader age categories, age dis-
tribution differences across the four BMI categories were taken into account for men and
women separately. Third, we calculated the age-sex standardized risk differences for outcome
for the four BMI categories, taking normal BMI as the reference. Fourth, after stratification for
age (<65y or65y), we conducted a Cox proportional hazards (PH) regression analysis,
obtaining hazard ratios (HR) estimating the effect of BMI and age on outcome, using a BMI of
20–24 kg/m2 of each group as the reference. Fifth, we performed the PH analyses within the
two broad age groups (<65y or65y) using a BMI of 20–24 kg/m2 in younger patients as the
reference to allow for comparison of the effect of obesity between younger and older patients.
For all PH analyses we present crude results, and also results adjusted for age, sex, and smok-
ing. In a separate model we also adjusted for history of cardiovascular disease. We did not con-
trol for variables that we considered likely causal intermediates, such as hypertension, diabetes
mellitus, and hypercholesterolemia [19]. In the PH regression models the proportionality
assumption for each covariate was checked by adding the product term with the logarithm of
follow-up time [23]. Finally, we evaluated the interaction between age (<65y or65y) and
obesity by assessing departures from additivity of effects [24–28]. We calculated the attribut-
able proportion (AP) due to interaction, which is the proportion of the effect among patients
with both risk factors that represents greater than additive effects.
Because start of dialysis, kidney transplantation and death are competing risks, we per-
formed competing risk analyses for younger and older pre-dialysis separately. First, start of
dialysis was taken as the event of interest, and death as the competing event. Second, start of
dialysis or death was taken as the event of interest, and kidney transplantation as the compet-
ing event. According to the so-called subdistribution hazard (SH) approach, individuals who
experience a competing event remain in the risk set instead of being censored, although they
are no longer at risk of the event of interest [29]. The SH ratio (SHR) represents a ratio in a
non-existing hypothetical population including those who experienced the competing event.
Finally, since starting dialysis is a shared clinical decision of the nephrologist based on prog-
nosis, we also analyzed the effect of BMI on the rate of kidney function decline. We used a lin-
ear mixed model (LMM) to estimate the effect of BMI on the rate of decline in kidney function
during the first two years of pre-dialysis care. All patients (n = 454) for whom kidney function
was available at baseline were included in this analyses. The rationale for not using complete
follow-up data is that stable patients who are still on pre-dialysis care after two years would
contribute a relative large effect toward the average kidney function decline. The LMM takes
into account that repeated measurements of the same patient are correlated [30].
For the standardization and calculation of risk differences we used Episheet (krothman.org/
episheet.xls). For the CR and LMM analysis we used Stata version 14. This statistical software
provides a method that fits competing risks regression models according to the SH method.
All other aforementioned analyses were done using SPSS 24.0 (SPSS, Inc. Chicago, IL).
Results
After excluding 10 patients, 5 with missing weight and 5 with missing height at baseline, 492
patients (98%) were included in the main analysis. The mean (±SD) age of the study cohort
Obesity, death or dialysis in pre-dialysis patients
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was 65±14 years, and 68% of the patients were men. The median (IQR) BMI was 26.0 (23.4–
29.5) kg/m2, with an approximately normal distribution. The distribution of the pre-dialysis
patients per category of BMI at baseline was: <20 (6%), 20 to 24 (36%), 25 to 29 (36%), and
30 (23%) kg/m2. Table 1 presents the baseline characteristics of the younger (<65 years) and
older ( 65 years) pre-dialysis patients.
The median (IQR) follow-up time for younger and older patients was 16 (7–31) and 16 (7–
32) months, respectively. For younger patients the cumulative proportions that started dialysis
or died by the end of follow-up was 66% and 4%, respectively, based on a life-table calculation,
and for older patients these proportions were 64% and 14%. Table 2 shows the crude and age-
sex standardized rates for the composite endpoint for younger and older pre-dialysis patients.
S1 Table shows the crude rates for the separate endpoints of start of dialysis, mortality and kid-
ney transplantation for younger and older pre-dialysis patients. The age-sex standardized com-
posite endpoint rate was 2.3 times higher in younger obese patients than in younger patients
with a normal BMI. In older pre-dialysis patients, differences in rates for the combined end-
point of start of dialysis or death were smaller between obese patients and those with a normal
BMI. Thus, obesity appears to be a strong risk factor for start of dialysis or mortality among
younger patients but a weaker risk factor among older pre-dialysis patients.
We checked the PH assumption and no sign of violation was found. After stratification by
age group (<65y or65y) and adjustment for sex, smoking, and cardiovascular disease, we
observed a U-shaped relation between BMI and start of dialysis-mortality among younger pre-
dialysis patients, with a similar but milder pattern among older patients (Table 3). After multi-
variable adjustment the hazard ratios (95% CI) for the combined outcome for obesity were
1.81 for younger patients and 1.30 for older patients. In contrast to younger patients, in older
pre-dialysis patients a low BMI at baseline was a stronger risk factor than obesity for the com-
bined endpoint. Additional adjustment for serum albumin, baseline eGFR or alcohol con-
sumption did not materially change the results (data not shown). Adjustment for diabetes,
hypertension and dyslipidemia, attenuated the relation between obesity and outcome as
expected. A sensitivity analysis in patients with diabetes showed a similar trend (data not
shown). After exclusion of patients with a history of cardiovascular disease at baseline and
adjustment for age, sex and smoking, the hazard ratios (95% CI) for the combined outcome by
category of increasing BMI were for younger patients: 0.91 (0.39, 2.09), 1 (reference), 1.42
(0.89, 2,26) and 1.54 (0.95, 2.48), and for older patients: 1.62 (0.86, 3.04), 1 (reference) 1.22
(0.83, 1.81) and 1.21 (0.77, 1.90), respectively. After excluding patients with extremely low
BMI (<18.5 kg/m2) the results did not materially change.
Our analysis to explore interaction between obesity and age (<65y or 65y) showed an AP
due to interaction of -0.18, (Table 4). This result implies an effect of joint exposure that is less
than the sum of the separate effects, a feature of biological antagonism. In contrast, an evalua-
tion of the interaction between low BMI and age of 65y showed an AP of 0.48, indicating a
joint effect of older age and low BMI that is considerably greater than the sum of their separate
effects. Indeed, in Table 2, one notes that low BMI is a strong risk factor among the older
patients but is associated with slightly lower risk among younger patients.
If start of dialysis is taken as the event of interest and death is a censoring point, the HRs
(95% CI) from the Cox-model after multivariable adjustment, for increasing category of BMI,
were 0.92 (0.41–2.07), 1 (reference), 1.64 (1.06–2.52) and 1.77 (1.14–2.76) for younger patients
and 1.81 (0.94–3.46), 1 (reference), 1.43 (1.00–2.05) and 1.64 (1.09–2.48) for older pre-dialysis
patients. In the competing risk analysis, taking start of dialysis as the event of interest and
death as the competing event, after multivariable adjustment the SHRs (95% CI) by category of
increasing BMI were 0.90 (0.38–2.12), 1 (reference), 1.47 (0.96–2.24) and 1.72 (1.15–2.59) for
younger patients and 1.68 (0.93–3.02), 1 (reference), 1.50 (1.05–2.14) and 1.80 (1.23–2.65) for
Obesity, death or dialysis in pre-dialysis patients
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Table 1. Baseline characteristics of the cohort of incident pre-dialysis patients for younger (<65y)
and older (65y) pre-dialysis patients.
Characteristics Age <65y Age65y
Total No. (%) 212 (43) 280 (57)
Age, y 51.2 (10.2) 75.3 (5.7)
Men, No. (%) 134 (63) 199 (71)
Ethnicity, No. (%)
white 187 (88.2) 267 (95.4)
black 5 (2.4) 11 (3.9)
asian 17 (8.0) 0 (0)
another 3 (1.4) 2 (0.7)
Primary kidney disease, No. (%)
diabetes 28 (13) 40 (14)
glomerulonephritis 41 (19) 24 (9)
renal vascular disease 38 (18) 114 (41)
other 105 (50) 102 (36)
History of cardiovascular disease, No. (%)
myocardial infarction 19 (9.0) 50 (17.9)
cerebrovascular accident 17 (8.0) 50 (17.9)
Smoking status, No. (%)
current 78 (36.8) 152 (54.3)
former 47 (22.2) 51 (18.2)
never 87 (41.0) 77 (27.5)
Diabetes Mellitus, No. (%) 45 (21) 83 (30)
history of Diabetes mellitus, y 15 (5, 18) 12 (7, 20)
Weight (kg) 81.8 (18.4) 77.6 (15.2)
BMI (kg/m2) 27.2 (5.7) 26.5 (4.7)
<20 (low), No. (%) 13 (6.0) 16 (5.6)
20 to 24 (normal), No. (%) 77 (35.6) 98 (34.3)
25 to 29 (overweight), No. (%) 62 (28.7) 113 (39.5)
30 (obese), No. (%) 60 (27.8) 53 (18.5)
Waist (cm)
men 103 (15.4) 103 (11.0)
women 95 (15.5) 98 (18.3)
Alcohol use (yes/no), No./Total No. (%) 104/212 (49.1) 125/278 (45.0)
Systolic blood pressure, mmHg 139 (20) 145 (23)
Diastolic blood pressure, mmHg 81 (11) 76 (12)
blood-pressure lowering drugs, No.(%) 175/187 (93.6) 229/240 (95.4)
eGFR ml/min per 1.73 m2 14.0 (10.6, 19.0) 14.5 (11.5, 18.1)
Total cholesterol (mmol/L) 4.6 (1.2) 4.3 (1.1)
statin use, No.(%) 103/187 (55) 150/240 (63)
CRP (mg/L) 4 (2–6) 6 (3–12)
Serum albumin (g/L) 41.7 (5.0) 40.0 (4.3)
Data are presented as median (interquartile range), mean (±SD) or number (percentage of the total).
BMI, body mass index; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate.
https://doi.org/10.1371/journal.pone.0184007.t001
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older patients. The SHR of 1.72 in younger and 1.80 in older obese patients reflect the start of
dialysis rate ratio among younger and older obese pre-dialysis patients who are alive or have
already died without dialysis treatment. After taking start of dialysis or death as the event and
kidney transplantation as the competing event, after multivariable adjustment the SHRs (95%
CI) by category of increasing BMI were 1.17 (0.49–2.78), 1 (reference), 1.93 (1.27–2.93) and
Table 2. Crude and age/sex standardized rates (95% CIs) and risk differences (95% CIs) for combined start of dialysis-mortality by BMI category
for younger (<65 years) and older (65 years) pre-dialysis patients.
Age group BMI (kg/m2)
<65 years <20 20 to 24 25 to 29 30
Number of patients 13 77 62 60
Person years 30.51 160.87 110.76 106.79
Dialysis-deaths (total) 7–0 (7) 43–1 (44) 44–4 (48) 48–2 (50)
Dialysis-deaths/100 py
Crude 22.94 27.35 43.34 46.82
95% CI 11.40, 39.81 21.03, 34.68 34.41, 52.53 37.55, 56.13
Age-sex standardized 11.76 28.01 55.01 63.23
95% CI 2.03, 21.49 19.46, 36.57 3.27, 77.38 4.10, 85.43
Risk difference -16.26 reference 27.00 35.21
95% CI -29.21, -3.30 reference 3.06, 50.95 11.42, 59.01
65 years
Number of patients 16 98 113 53
Person years 22.75 203.59 198.57 97.72
Dialysis-deaths (total) 12–3 (15) 52–19 (71) 74–13 (87) 42–3 (45)
Dialysis-deaths/100 py
Crude 65.93 34.87 43.81 46.05
95% CI 44.89, 81.19 28.60, 41.57 37.01, 50.66 36.39, 55.57
Age-sex standardized 106.41 37.46 48.78 52.11
95% CI 12.70, 200.11 28.37, 46.54 34.58, 62.97 33.87, 70.35
Risk difference 68.95 reference 11.32 14.65
95% CI -25.20, 163.10 reference -5.54, 28.18 -5.73, 35.03
BMI: body mass index, CI: confidence interval, py: person year
https://doi.org/10.1371/journal.pone.0184007.t002
Table 3. Rate ratios of start of dialysis-mortality during follow-up, with 95% confidence intervals, from proportional hazards regression for BMI at
baseline for younger (<65 years) and older (65 years) pre-dialysis patients. Normal BMI in each age category was taken as the reference category.
BMI per age group Crude Age and sex adjusted Age, sex and smoking adjusted Multivariable adjusted*
Younger
low BMI 0.90 (0.40, 2.00) 0.90 (0.40, 2.02) 0.89 (0.40, 2.00) 0.92 (0.41, 2.09)
normal BMI 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
high BMI 1.63 (1.08, 2.45) 1.63 (1.08, 2.46) 1.66 (1.10, 2.50) 1.76 (1.16, 2.68)
obese 1.68 (1.12, 2.53) 1.70 (1.12, 2.59) 1.68 (1.10, 2.56) 1.81 (1.17, 2.81)
Older
low BMI 1.86 (1.06, 3.26) 1.83 (1.04, 3.21) 1.77 (1.00, 3.13) 1.73 (0.97, 3.08)
normal BMI 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
high BMI 1.24 (0.91, 1.70) 1.24 (0.90, 1.70) 1.25 (0.91, 1.72) 1.25 (0.91, 1.71)
obese 1.31 (0.90, 1.90) 1.30 (0.89, 1.90) 1.31 (0.89, 1.91) 1.30 (0.89, 1.90)
* Multivariable adjustment: age, sex, smoking (current, former or never), co-morbidity (history of cardiovascular disease: myocardial infarction or CVA).
https://doi.org/10.1371/journal.pone.0184007.t003
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1.96 (1.28–2.98) for younger patients and 1.88 (1.15–3.05), 1 (reference), 1.31 (0.95–1.80) and
1.42 (0.98–2.05) for older patients. Due to the low number of deaths in younger patients, we
could not perform a competing risk analysis in which death could be taken as the event of
interest (S1 Table).
eGFR measurements were available for 454 (94%) out of 482 pre-dialysis patients. The
median number of eGFR measurements during the first 2 years of follow-up was 3 (IQR 2–4)
and 10%, 33%, 57% of these patients had 1, 23 measurements, respectively. The overall kid-
ney function decline for all pre-dialysis patients was -0.15 (95% CI: -0.19, -0.12) ml/min/
1.73m2 per month. There was no indication of effect modification between age and BMI with
regard to eGFR decline. Fig 1 shows the multivariable adjusted kidney function decline
according the four BMI categories at baseline during 2 years of follow-up for younger and
older pre-dialysis patients separately. At baseline, after multivariable adjustment, the difference
in kidney function (95%-CI) compared with the reference category was, for low BMI, 1.09
(-1.16, 3.35), and for high BMI -2.01 (-3.23, -0.79), and for obesity -2.06 (-3.45, -0.68) (S2
Table). Table 5 shows the crude and adjusted monthly kidney function change for the pre-dial-
ysis patients according to the four BMI categories at baseline. Compared with patients with a
normal BMI, after multivariable adjustment patients with obesity had similar renal function
decline.
Discussion
This cohort study of incident pre-dialysis patients shows that obesity (BMI30 kg/m2), inde-
pendent of important confounders, is associated with approximately 2-fold stronger risk for
start of dialysis or death in younger (<65y) patients, compared with patients with normal
weight. In older (65y) pre-dialysis patients, low BMI was a stronger risk factor than obesity
for start of dialysis or mortality. Obese patients had a similar kidney function decline com-
pared with patients with a normal BMI.
Table 4. Rate ratios of start of dialysis-mortality during follow-up, with 95% confidence intervals, from proportional hazards regression for BMI at
baseline for younger (<65 years) and older (65 years) pre-dialysis patients. For interaction analysis normal BMI among younger patients was taken as
the reference.
BMI per age group Crude Sex adjusted Sex and smoking adjusted Multivariable adjusted*
Younger
low BMI 0.88 (0.40, 1.96) 0.88 (0.40, 1.97) 0.87 (0.39, 1.95) 0.88 (0.39, 1.97)
normal BMI 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
high BMI 1.61 (1.07, 2.42) 1.61 (1.07, 2.42) 1.63 (1.08, 2.45) 1.64 (1.09, 2.47)
obese 1.71 (1.14, 2.56) 1.71 (1.14, 2.56) 1.68 (1.12, 2.52) 1.69 (1.13, 2.55)
Older
low BMI 2.32 (1.29, 4.17) 2.32 (1.29, 4.17) 2.16 (1.19, 3.91) 2.18 (1.20, 3.95)
normal BMI 1.28 (0.88, 1.86) 1.28 (0.88, 1.86) 1.26 (0.86, 1.83) 1.25 (0.86, 1.82)
high BMI 1.57 (1.09, 2.26) 1.57 (1.09, 2.26) 1.56 (1.08, 2.25) 1.55 (1.08, 2.24)
obese 1.65 (1.09, 2.50) 1.65 (1.09, 2.51) 1.64 (1.08, 2.48) 1.64 (1.08, 2.48)
AP
low BMI 0.50 (0.32, 0.78) 0.50 (0.32, 0.78) 0.48 (0.29, 0.79) 0.48 (0.29, 0.79)
obese -0.21 (-0.30, 0.06) -0.21 (-0.30, 0.06) -0.18 (-0.35, 0.09) -0.18 (-0.36, 0.08)
*Multivariable adjustment: sex, smoking (current, former or never), co-morbidity (history of cardiovascular disease: myocardial infarction or CVA).
AP: Attributable Proportion to interaction with 95% CI. To quantify the amount of interaction on an additive scale, we calculated the AP = (HR++—HR+-—
HR
-+ +1)/HR++, which is the proportion of outcome that is due to interaction among patients with both exposures. Exposure refers to obese or low BMI
versus normal BMI and old versus young pre-dialysis patients. In the absence of interaction on an additive scale AP equals 0.
https://doi.org/10.1371/journal.pone.0184007.t004
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Fig 1. Kidney function decline in incident younger (<65 years) and older (65 years) pre-dialysis patients
according to BMI category at baseline during 2 years of follow-up. Multivariable adjusted: age, sex, smoking
(current, former or never), co-morbidity (history of cardiovascular disease: myocardial infarction or CVA).
https://doi.org/10.1371/journal.pone.0184007.g001
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Our findings are consistent with large studies performed in individuals with early to mod-
erate stages of CKD (stages 1–3) showing that a high BMI is a risk factor for ESRD [31–33]. A
recent study (>3 million individuals, mean age 60y) showed that a BMI30 kg/m2 is associ-
ated with rapid loss of kidney function (>5 ml/min/1.73m2 per year) in patients older than 40
years with eGFR>60 mL/min per 1.73 m2 [33]. A BMI between 25 and 30 kg/m2 was associ-
ated with lowest risk of kidney function decline. In contrast, a study in non-diabetic CKD
stage 3–5 patients found little relation between obesity and RRT or kidney function decline
[34]. That study, however, did not control for confounding by smoking, and patients with low
BMI were grouped with the reference category, both of which may have contributed to an
underestimation of the effect of obesity [35]. Another large cohort study showed little effect of
obesity on risk of ESRD in patients with an eGFR <30 ml/min/1.73m2 [36]. However, smok-
ing was likewise not controlled in that study, which again may have contributed to an underes-
timation of the effect of obesity. Furthermore, in contrast to our study with incident patients,
the cohort comprised prevalent pre-dialysis patients, which may have resulted in survivor bias
[37].
We took for our main analysis the composite outcome, start of dialysis or death, since death
is a competing risk for start of dialysis, with risk of death increasing with age. In addition, start-
ing dialysis is a shared decision of both the nephrologist and patient based on prognostic fac-
tors such as life expectancy and rate of kidney function decline, as well as uremic symptoms
and fluid overload. For all age groups mortality rates increase substantially at eGFR<30 ml/
min/1.73m2, being about 7% between 18-64y and 14% between 65-84y of age [38]. A 2-year
follow-up study in CKD stage 4 patients reported 7% deaths and 25% RRT, and in an elderly
population at 4 years 45% deaths and 23% RRT [10,13]. The relative risk for death associated
with each level of kidney function decreases markedly by age as a result of higher background
mortality risk [38]. A competing risk influences the opportunity for an event to occur. For
example, in the present study a patient may have died before start of dialysis has occurred. We
found in our competing-risk analysis a slightly higher risk of start of dialysis in obese patients
compared with patients with a normal BMI. Younger obese pre-dialysis patients had a 1.7-fold
increased risk and in older obese pre-dialysis patients we found a 1.8-fold increased risk for
starting dialysis. In addition, older patients with a low BMI had about 1.7-fold increased risk of
start of dialysis or death compared with those with a normal BMI, which might be attributable
to malnutrition from identified or subclinical diseases [39].
In the PH analyses we censored at the time of kidney transplantation, which may have led
to bias in estimating the effect of BMI as a result of differential selection for kidney transplanta-
tion, to the extent we could not control completely for covariates related to the selection for
kidney transplantation. However, in the competing risk analyses, when taking kidney trans-
plantation as the competing risk we found similar effects of obesity in younger and older pre-
Table 5. Monthly kidney function decline with 95% confidence intervals among incident pre-dialysis patients during 2 years of follow-up accord-
ing to BMI category at baseline.
BMI group N Crude Age, sex and smoking adjusted Multivariable adjusted*
low BMI 28 -0.12 (-0.36, 0.11) -0.12 (-0.36, 0.11) -0.15 (-0.38, 0.07)
normal BMI 163 -0.15 (-0.21, -0.09) -0.15 (-0.21, -0.09) -0.15 (-0.21, -0.09)
high BMI 163 -0.13 (-0.18, -0.08) -0.13 (-0.18, -0.08) -0.12 (-0.17, -0.07)
obese 100 -0.16 (-0.22, -0.10) -0.16 (-0.22, -0.10) -0.16 (-0.23, -0.10)
*Multivariable adjusted: age, sex, smoking (current, former or never), co-morbidity (history of cardiovascular disease: myocardial infarction or CVA).
https://doi.org/10.1371/journal.pone.0184007.t005
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dialysis patients. In the Netherlands in 6 out of 7 kidney transplantation centers, pre-emptive
kidney transplantation is suspended for patients with a BMI30 kg/m2, resulting in differen-
tial selection of healthy patients with a BMI<30 kg/m2 for pre-emptive kidney transplantation.
In addition, pre-emptive kidney transplantation is scheduled for patients with an eGFR
between 10–15 ml/min/1.73m2, whereas dialysis is commenced in patients with an eGFR<10
ml/min/1.73m2. Finally, the age of 70 years or older is a contra-indication for kidney trans-
plantation if there is history of cardiovascular disease or diabetes.
The adverse effect of low BMI among older patients was notable, as was its absence among
younger patients. The reason for this difference is unclear, as we have controlled for cardiovas-
cular risk factors. It may simply be a chance finding. Both younger and older obese pre-dialysis
patients had at baseline a lower kidney function compared with those with a normal BMI (Fig
1A and 1B). The lower kidney function may be a result of the history of obesity. The rate of
kidney function decline was comparable among the four BMI categories during 24 months of
follow-up. A longer follow-up might have shown larger differences in rate of function decline
between the four BMI groups.
Our study had important limitations. First, risks related to obesity rise gradually, becoming
appreciable only after at least 5 years of obesity [9]. In this study, we had no information about
the duration of obesity. Second, we combined the outcomes, start of dialysis and death,
because the number of deaths was too few to study the risks related to four BMI categories.
Third, we used BMI as a proxy for obesity [40]. BMI does not fully reflect some age-related
changes, such as the increasing proportion of body fat and decreasing muscle mass. Fourth,
failure to control for unintentional weight loss could result in residual confounding. Loss of
body mass, even in obese pre-dialysis patients, might result in greater mortality. We did not
control for the amount of tobacco smoked by patients, which may have resulted in residual
confounding. However, if anything, such residual confounding would tend to underestimate
the effect of obesity. Finally, our results may not apply to all CKD 4–5 patients, as we studied
only those receiving specialized pre-dialysis care in an outpatient clinic.
In conclusion, younger obese pre-dialysis patients have an increased risk for start of dialysis
and death compared with those with a normal BMI. In contrast, underweight was a stronger
risk factor than obesity in older pre-dialysis patients for start of dialysis and death.
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